Related by context. Frequent words. (Click for all words.) 63 PEGylation technology 62 active cellular immunotherapy 62 online pharmacy CVS.com 62 unique PER.C6 ® 62 transmucosal film 61 Neo Urinary Conduit 61 Medarex applies 61 leading lipid nanoparticle 60 aesthetic medicine BioLook 60 low toxicity bioscience 60 PEG PAL PEGylated recombinant 58 mediate RNAi 58 NPS complements 57 Dyax utilizes 56 ZymoGenetics intends 56 novel RNAi therapeutics 55 phenylalanine ammonia lyase 55 Panzem R 54 Medarex logo 54 Oral Suspension Oral Suspension 54 USP ANUSOL HC 54 monobasic monohydrate USP 53 * Azixa 53 phenylketonuria PKU developed 53 mg Suppository Hydrocortisone Acetate 53 LabCorp combines 53 sodium phosphate monobasic monohydrate 52 proprietary Mimetic Ligand 52 molecular chaperone 52 By THERESA CAMPBELL 52 topically delivered 52 candidate brentuximab vedotin 51 Nasdaq CRXL 51 TISMAN 51 platinum chromium alloy 51 ALN TTR# 51 Potassium Chloride Sodium Ascorbate 51 Thiarabine 51 electrolytically generated source 51 AeroLEF R 51 pramlintide acetate injection 51 triple VEGF receptor 51 Ladbrokes.tv 51 PUBLIC WEBSITE WWW.FITCHRATINGS.COM 51 By MICHAEL FORTUNA 51 LEX System 50 By Priyanka Dayal 50 Medipoints 50 ALN TTR 50 By Thomas Gryta 50 INACCURACIES IN THE DOW 50 DEBT AND IDENTITY 50 Sangamo ZFP technology 50 REPORTS FILED FROM 50 novel bioadhesive drug 49 PINNACLEDIGEST.COM S PAST PERFORMANCE 49 Synta scientists 49 VERIFICATION OF THE 49 Encompix provides 49 2 methoxyestradiol 49 inhaled formulation 49 TIMES REPUBLICAN 49 Captisol 49 activity dependent neuroprotective 49 CONTAIN FORWARD LOOKING STATEMENTS 49 Ariba Sourcing Ariba Spend 49 THE COPYRIGHT LAWS OF 49 boron chemistry 49 B lymphocyte stimulator 49 SHALL NOT CONSTITUTE AN 49 IS PROTECTED BY 49 BE DELAYS OMISSIONS OR 48 BY REBECCA GOODMAN 48 R daptomycin 48 protein ADNP 48 MATERIALLY FROM ANY FUTURE 48 Sodium Sulfate Sodium Chloride 48 BE ANY SALE 48 REGULATORY AUTHORITY HAS APPROVED 48 Amgen discovers develops manufactures 48 THE AMERICANS HAVE 48 MATTERS DISCUSSED IN 48 By MIKE SACCONE 48 THAT ARE SUBJECT TO 48 histone deacetylase HDAC inhibitor 48 NASDAQ CRXL 48 IS NOT INDICATIVE OF 48 ARE REASONABLE THERE CAN 48 POGO ™ 48 Amgen discovers develops 48 HISTORICAL INFORMATION PRESENTED HEREIN 48 IN THIS PROFILE 48 UMBLE 48 BiTE R 48 RISK FACTORS DISCLOSED IN 47 THE COMPANY 'S PERIODIC 47 perifosine novel potentially 47 Microcyn Technology platform 47 Visibility Ariba Travel 47 By Gordon Wilczynski 47 CHEAP ONLINE PHARMACY BEST